Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jun 1;97(11):2562–2568. doi: 10.1172/JCI118704

Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators.

D Salvemini 1, M G Currie 1, V Mollace 1
PMCID: PMC507342  PMID: 8647949

Abstract

We have evaluated the contributions of nitric oxide (NO) and prostacyclin (PGI2) in the in vivo antiplatelet effects of clinically useful nitrovasodilators. In rats, intravenous infusion of three NO donors, glyceryl trinitrate, sodium nitroprusside, or 3'-morpholinosydnonimine, the stable metabolite of molsidomine, released 6-keto PGF1alpha (the stable metabolite of PGI2) and inhibited ex vivo human platelet aggregation to adenosine diphosphate by at least 80%. In in vitro studies, glyceryl trinitrate, sodium nitroprusside, and 3'-morpholinosydnonimine, at clinically attainable concentrations, increased cyclooxygenase activity in endothelial cells (EC), which resulted in a four- to sixfold release of 6-keto PGF1alpha. Pretreatment of the EC with hemoglobin which binds to and inactivates the biological actions of NO, but not by methylene blue (MelB), attenuated the NO-mediated PGI2 from the EC by at least 70%. Release of 6-keto PGF1alpha by the NO donors increased the ability of these compounds to inhibit thrombin-induced human platelet aggregation by at least 10 times; this potentiation was inhibited by hemoglobin but not by MeB. MeB blocked the direct anti-platelet effect of the NO donors in the absence of EC. In summary, we have demonstrated that NO, directly as well as together with an NO-driven cyclooxygenase activation (and hence PGI2), release contributes to the marked anti-platelet effects observed after the in vivo administration of clinically used nitrovasodilators.

Full Text

The Full Text of this article is available as a PDF (191.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anggård E. E. Endogenous nitrates--implications for treatment and prevention. Eur Heart J. 1991 May;12 (Suppl A):5–8. [PubMed] [Google Scholar]
  2. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  3. DeWitt D. L. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta. 1991 May 8;1083(2):121–134. doi: 10.1016/0005-2760(91)90032-d. [DOI] [PubMed] [Google Scholar]
  4. Dinerman J. L., Lowenstein C. J., Snyder S. H. Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease. Circ Res. 1993 Aug;73(2):217–222. doi: 10.1161/01.res.73.2.217. [DOI] [PubMed] [Google Scholar]
  5. Feelisch M., Kelm M. Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun. 1991 Oct 15;180(1):286–293. doi: 10.1016/s0006-291x(05)81290-2. [DOI] [PubMed] [Google Scholar]
  6. Fletcher J. R., Ramwell P. W., Harris R. H. Thromboxane, prostacyclin, and hemodynamic events in primate endotoxin shock. Adv Shock Res. 1981;5:143–148. [PubMed] [Google Scholar]
  7. Harper J. F., Brooker G. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res. 1975;1(4):207–218. [PubMed] [Google Scholar]
  8. Ignarro L. J., Lippton H., Edwards J. C., Baricos W. H., Hyman A. L., Kadowitz P. J., Gruetter C. A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981 Sep;218(3):739–749. [PubMed] [Google Scholar]
  9. Ignarro L. J. Nitric oxide-mediated vasorelaxation. Thromb Haemost. 1993 Jul 1;70(1):148–151. [PubMed] [Google Scholar]
  10. Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest. 1985 Aug;76(2):703–708. doi: 10.1172/JCI112024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Misko T. P., Schilling R. J., Salvemini D., Moore W. M., Currie M. G. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem. 1993 Oct;214(1):11–16. doi: 10.1006/abio.1993.1449. [DOI] [PubMed] [Google Scholar]
  12. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest. 1986 Jul;78(1):1–5. doi: 10.1172/JCI112536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Needleman P., Jakschik B., Johnson E. M., Jr Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther. 1973 Nov;187(2):324–331. [PubMed] [Google Scholar]
  14. Nishikawa M., Kanamori M., Hidaka H. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites. J Pharmacol Exp Ther. 1982 Jan;220(1):183–190. [PubMed] [Google Scholar]
  15. Parker J. O. Nitrate therapy in stable angina pectoris. N Engl J Med. 1987 Jun 25;316(26):1635–1642. doi: 10.1056/NEJM198706253162606. [DOI] [PubMed] [Google Scholar]
  16. Radomski M. W., Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemost. 1993 Jul 1;70(1):36–41. [PubMed] [Google Scholar]
  17. Salvemini D., Manning P. T., Zweifel B. S., Seibert K., Connor J., Currie M. G., Needleman P., Masferrer J. L. Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J Clin Invest. 1995 Jul;96(1):301–308. doi: 10.1172/JCI118035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Salvemini D., Misko T. P., Masferrer J. L., Seibert K., Currie M. G., Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7240–7244. doi: 10.1073/pnas.90.15.7240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Salvemini D., Mollace V., Pistelli A., Anggard E., Vane J. Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):982–986. doi: 10.1073/pnas.89.3.982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Salvemini D., Radziszewski W., Korbut R., Vane J. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol. 1990 Dec;101(4):991–995. doi: 10.1111/j.1476-5381.1990.tb14194.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Salvemini D., de Nucci G., Gryglewski R. J., Vane J. R. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6328–6332. doi: 10.1073/pnas.86.16.6328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Salvemini D., de Nucci G., Sneddon J. M., Vane J. R. Superoxide anions enhance platelet adhesion and aggregation. Br J Pharmacol. 1989 Aug;97(4):1145–1150. doi: 10.1111/j.1476-5381.1989.tb12572.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schafer A. I., Alexander R. W., Handin R. I. Inhibition of platelet function by organic nitrate vasodilators. Blood. 1980 Apr;55(4):649–654. [PubMed] [Google Scholar]
  24. Seibert K., Masferrer J. L. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor. 1994 Spring;4(1):17–23. [PubMed] [Google Scholar]
  25. Stamler J. S., Loscalzo J. The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. J Am Coll Cardiol. 1991 Nov 15;18(6):1529–1536. doi: 10.1016/0735-1097(91)90686-4. [DOI] [PubMed] [Google Scholar]
  26. Steiner A. L., Parker C. W., Kipnis D. M. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem. 1972 Feb 25;247(4):1106–1113. [PubMed] [Google Scholar]
  27. Tateson J. E., Moncada S., Vane J. R. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins. 1977 Mar;13(3):389–397. doi: 10.1016/0090-6980(77)90019-3. [DOI] [PubMed] [Google Scholar]
  28. Vane J. R., Anggård E. E., Botting R. M. Regulatory functions of the vascular endothelium. N Engl J Med. 1990 Jul 5;323(1):27–36. doi: 10.1056/NEJM199007053230106. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES